Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Thomas W. Flaig, Jonathan E. Rosenberg, Christopher J. Hoimes, Peter H. O'Donnell, Nataliya Mar, Theodore Stewart Gourdin, Stephanie Henry, Mehmet Asim Bilen, Saby George, Pedro C. Barata, Sandy Srinivas, Santosh Keshay Rao, Vasily J. Assikis, Earle F Burgess, Chethan Ramamurthy, Gabriel P. Haas, Jason Jerome Lukas, Shirly Mildiner-Earley, Yao Yu, Daniel P. Petrylak
Institutions: University of Colorado Cancer Center, Memorial Sloan Kettering Cancer Center, Duke University, Duke Cancer Institute, University of Chicago, University of California, Irvine Medical Center, Medical University of South Carolina, MUSC Hollings Cancer Center, UCLouvain, Winship Cancer Institute, Roswell Park Comprehensive Cancer Center, University Hospitals of Cleveland, University Hospitals Seidman Cancer Center, Stanford Medicine, Stanford University, University Hospitals Cleveland Medical Center, Piedmont Cancer Institute, Levine Cancer Institute, The University of Texas MD Anderson Cancer Center, Astellas Pharma (United States), Seagen (United States), Yale Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379332801